Eiken Chemical (4549) Fundamentals 2026 — P/E 22.8x, Revenue Analysis | SniperIQ
Eiken Chemical (4549) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥84.5B, trading at ¥2562.00 on the JPX. This SniperIQ fundamentals page covers Eiken Chemical's valuation (P/E 22.8x, P/B 1.9x), profitability (net margin 8.8%), revenue (¥41.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Eiken Chemical's market cap?
Eiken Chemical (4549) has a market capitalization of approximately ¥84.5B, trading at ¥2562.00 on the JPX. Market cap moves with the live share price.
What is Eiken Chemical's P/E ratio?
Eiken Chemical's trailing twelve-month P/E ratio is 22.8x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Eiken Chemical?
Eiken Chemical runs a net profit margin of 8.8%, a gross margin of 38.6%, and an operating margin of 7.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Eiken Chemical generate?
Eiken Chemical reported revenue of ¥41.9B for fiscal year 2025, with net income of ¥3.7B and earnings per share (EPS) of 112.5. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Eiken Chemical pay a dividend?
Eiken Chemical offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Eiken Chemical financially healthy?
Eiken Chemical carries a debt-to-equity ratio of 0.17x and a current ratio of 2.19x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Eiken Chemical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Eiken Chemical (4549) the key facts are: market cap ¥84.5B, P/E 22.8x, revenue ¥41.9B, 52-week range 2113-3500. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Eiken Chemical's full fundamentals live
Get Eiken Chemical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.